Inga Back, MPH

Researchers evaluated the effect of statin use on risk for cardiovascular disease, all-cause mortality, and type 2 diabetes in patients with rheumatoid arthritis.

Based on results from the ORAL Surveillance trial, researchers of this study assessed the risk for cardiovascular outcomes with tofacitinib in patients with rheumatoid arthritis.

Researchers evaluated the link between hydroxychloroquine use and corrected QT length in patients with SLE and RA without cardiovascular disease.

Researchers identified independent risk factors for major adverse cardiovascular events in high-risk patients with rheumatoid arthritis receiving treatment with tofacitinib vs TNF inhibitors.

Researchers compared cardiovascular risk among patients with gout who received treatment with allopurinol vs benzbromarone.

The AHA has issued a Presidential Advisory Statement outlining considerations for addressing the effects of opioids on cardiovascular and neurovascular health.